Zena Wilson

2.4k total citations
21 papers, 742 citations indexed

About

Zena Wilson is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zena Wilson has authored 21 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zena Wilson's work include DNA Repair Mechanisms (8 papers), PARP inhibition in cancer therapy (6 papers) and Advanced Breast Cancer Therapies (4 papers). Zena Wilson is often cited by papers focused on DNA Repair Mechanisms (8 papers), PARP inhibition in cancer therapy (6 papers) and Advanced Breast Cancer Therapies (4 papers). Zena Wilson collaborates with scholars based in United Kingdom, United States and Brazil. Zena Wilson's co-authors include Alan Lau, Rajesh Odedra, Sylvie M. Guichard, Dan Heathcote, J. Willem M. Nissink, Kevin M. Foote, Christine Wood, Kevin Blades, Gary Wilkinson and James Yates and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Zena Wilson

21 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zena Wilson United Kingdom	11	458	316	123	107	72	21	742
Andrew McGown United Kingdom	11	325 0.7×	228 0.7×	111 0.9×	107 1.0×	56 0.8×	28	661
Martina S.J. McDermott United States	16	488 1.1×	438 1.4×	172 1.4×	104 1.0×	69 1.0×	33	969
Jianguo Ma China	18	487 1.1×	359 1.1×	156 1.3×	72 0.7×	26 0.4×	49	879
Christopher J. Matheson United States	13	647 1.4×	442 1.4×	128 1.0×	130 1.2×	98 1.4×	22	977
Mika Kontro Finland	13	505 1.1×	156 0.5×	142 1.2×	43 0.4×	77 1.1×	53	903
Ben Allal France	20	489 1.1×	347 1.1×	139 1.1×	44 0.4×	88 1.2×	32	918
Yeuan Ting Lee Malaysia	6	498 1.1×	300 0.9×	192 1.6×	197 1.8×	85 1.2×	9	1.0k
Michael A. Batey United Kingdom	8	704 1.5×	572 1.8×	94 0.8×	34 0.3×	68 0.9×	11	920
Nanni Huser United States	8	737 1.6×	238 0.8×	84 0.7×	79 0.7×	100 1.4×	15	999
Carlos M. Telleria Canada	11	345 0.8×	261 0.8×	188 1.5×	62 0.6×	78 1.1×	20	803

Countries citing papers authored by Zena Wilson

Since Specialization

Citations

This map shows the geographic impact of Zena Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zena Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zena Wilson more than expected).

Fields of papers citing papers by Zena Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zena Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zena Wilson. The network helps show where Zena Wilson may publish in the future.

Co-authorship network of co-authors of Zena Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Zena Wilson. A scholar is included among the top collaborators of Zena Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zena Wilson. Zena Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wenjuan, Michael P. Grams, Rajneet K. Oberoi, et al.. (2025). The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-Oncology. 27(9). 2250–2261. 1 indexed citations

Karmokar, Ankur, Adina Hughes, Zena Wilson, et al.. (2023). Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models. Cancers. 15(16). 4195–4195. 4 indexed citations

Staniszewska, Anna D., Joshua Armenia, Matthew King, et al.. (2022). PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. OncoImmunology. 11(1). 2083755–2083755. 37 indexed citations

Wallez, Yann, Theresa A. Proia, Elisabetta Leo, et al.. (2022). Abstract 1142: Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models. Cancer Research. 82(12_Supplement). 1142–1142. 2 indexed citations

Proia, Theresa A., Yann Wallez, Zena Wilson, et al.. (2022). Abstract P2-13-18: Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models. Cancer Research. 82(4_Supplement). P2–13. 2 indexed citations

Wallez, Yann, Theresa A. Proia, Ankur Karmokar, et al.. (2022). Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models. Cancer Research. 82(12_Supplement). 5298–5298. 1 indexed citations

Wijnhoven, Paul W.G., Antonio Ramos‐Montoya, Zena Wilson, et al.. (2020). Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 39(25). 4869–4883. 126 indexed citations

Méndez‐Lucas, Andrés, Wei Lin, Paul C. Driscoll, et al.. (2020). Identifying strategies to target the metabolic flexibility of tumours. Nature Metabolism. 2(4). 335–350. 100 indexed citations

Karp, Natasha A., et al.. (2020). A multi-batch design to deliver robust estimates of efficacy and reduce animal use – a syngeneic tumour case study. Scientific Reports. 10(1). 6178–6178. 22 indexed citations

10.

Young, Lucy A., Christelle de Renty, Margaret H. Veldman-Jones, et al.. (2019). Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Research. 79(14). 3762–3775. 54 indexed citations

11.

Ehrhardt, Beate, et al.. (2019). An innovative non-invasive technique for subcutaneous tumour measurements. PLoS ONE. 14(10). e0216690–e0216690. 13 indexed citations

12.

Jones, Gemma N., Claire Rooney, Martine P. Roudier, et al.. (2018). pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. British Journal of Cancer. 119(10). 1233–1243. 28 indexed citations

13.

Young, Lucy A., Oona Delpuech, Brandon S. Willis, et al.. (2018). Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models. Cancer Research. 78(13_Supplement). LB–263. 3 indexed citations

14.

Yates, James, Zena Wilson, Lucy A. Young, et al.. (2017). Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling. Cancer Research. 77(13_Supplement). 2494–2494. 2 indexed citations

15.

Hall, Anthony, Susan Ashton, Zena Wilson, et al.. (2015). PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary. Toxicologic Pathology. 44(1). 98–111. 10 indexed citations

16.

Savi, Chris De, Robert H. Bradbury, Alfred A. Rabow, et al.. (2015). Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. Cancer Research. 75(15_Supplement). 3650–3650. 4 indexed citations

17.

Sio, Terence T., Rajneet K. Oberoi, Michael P. Grams, et al.. (2014). The Impact of Hemi-brain Irradiation on Accumulation of PI3K/mTOR Inhibitors With Limited (GDC-0980) and Robust (GNE-317) Blood–Brain Barrier Penetration. International Journal of Radiation Oncology*Biology*Physics. 90(1). S197–S197. 2 indexed citations

18.

Brave, Sandra R., Kirsty Ratcliffe, Zena Wilson, et al.. (2011). Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family. Molecular Cancer Therapeutics. 10(5). 861–873. 72 indexed citations

19.

Partridge, E. A., et al.. (2007). Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (¹⁴C-ZD6126) to tumour-bearing mice. Xenobiotica. 37(3). 328–340. 9 indexed citations

20.

Bradley, Daniel P., Jean Tessier, Susan Ashton, et al.. (2007). Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats. Neoplasia. 9(5). 382–391. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact